$233 Million is the total value of Prosight Management, LP's 52 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 233.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | ISHARES TRput | $27,920,000 | – | 195,000 | +100.0% | 11.98% | – | |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $12,809,000 | +18.3% | 82,100 | +9.5% | 5.50% | +8.6% |
| CNC | Buy | CENTENE CORP DEL | $10,149,000 | +20.0% | 159,700 | +12.2% | 4.36% | +10.2% |
| CHNG | Buy | CHANGE HEALTHCARE INC | $9,297,000 | +66.4% | 830,100 | +48.5% | 3.99% | +52.9% |
| ACIU | Buy | AC IMMUNE SA | $7,920,000 | +8.3% | 1,176,801 | +11.2% | 3.40% | -0.6% |
| CI | Buy | CIGNA CORP NEW | $7,225,000 | +9.8% | 38,500 | +3.7% | 3.10% | +0.8% |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $6,938,000 | – | 118,000 | +100.0% | 2.98% | – |
| New | APTOSE BIOSCIENCES INC | $4,941,000 | – | 783,073 | +100.0% | 2.12% | – | |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $4,928,000 | +63.6% | 114,100 | +8.9% | 2.12% | +50.2% |
| CLLS | New | CELLECTIS S Aspon ads | $4,923,000 | – | 276,577 | +100.0% | 2.11% | – |
| ADMA | Buy | ADMA BIOLOGICS INC | $3,807,000 | +6.4% | 1,299,300 | +4.6% | 1.63% | -2.3% |
| BAX | New | BAXTER INTL INC | $3,659,000 | – | 42,500 | +100.0% | 1.57% | – |
| New | BRISTOL-MYERS SQUIBB COcall | $2,940,000 | – | 50,000 | +100.0% | 1.26% | – | |
| VCEL | New | VERICEL CORP | $2,901,000 | – | 209,897 | +100.0% | 1.24% | – |
| PCRX | New | PACIRA BIOSCIENCES | $2,886,000 | – | 55,000 | +100.0% | 1.24% | – |
| ESTA | Buy | ESTABLISHMENT LABS HLDGS INC | $2,376,000 | +29.8% | 127,173 | +0.4% | 1.02% | +19.3% |
| TPTX | New | TURNING POINT THERAPEUTICS I | $1,654,000 | – | 25,602 | +100.0% | 0.71% | – |
| TBIO | New | TRANSLATE BIO INC | $1,604,000 | – | 89,510 | +100.0% | 0.69% | – |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $1,495,000 | – | 92,000 | +100.0% | 0.64% | – |
| CARA | New | CARA THERAPEUTICS INC | $1,487,000 | – | 86,965 | +100.0% | 0.64% | – |
| MGTA | New | MAGENTA THERAPEUTICS INC | $1,266,000 | – | 168,578 | +100.0% | 0.54% | – |
| NEO | New | NEOGENOMICS INC | $1,203,000 | – | 38,819 | +100.0% | 0.52% | – |
| PRSC | New | PROVIDENCE SVC CORP | $1,178,000 | – | 14,923 | +100.0% | 0.51% | – |
| EVFM | New | EVOFEM BIOSCIENCES INC | $1,168,000 | – | 412,788 | +100.0% | 0.50% | – |
| BEAT | New | BIOTELEMETRY INC | $1,118,000 | – | 24,733 | +100.0% | 0.48% | – |
| XERS | New | XERIS PHARMACEUTICALS INC | $1,116,000 | – | 419,469 | +100.0% | 0.48% | – |
| APEN | Buy | APOLLO ENDOSURGERY INC | $621,000 | -4.2% | 379,945 | +12.7% | 0.27% | -11.9% |
| MGLN | New | MAGELLAN HEALTH INC | $379,000 | – | 5,200 | +100.0% | 0.16% | – |
| New | 1LIFE HEALTHCARE INCput | $291,000 | – | 8,000 | +100.0% | 0.12% | – | |
| New | ZOGENIX INCput | $221,000 | – | 8,200 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.